Could Microbiome-Based Therapeutics Fill the Unmet Need in Recurrent Clostridioides Difficile (C. Diff) Treatment? Spherix Investigates
While physicians express excitement surrounding products in the microbiome sector, current challenges with access to fecal microbiota transplants may translate into slow adoption EXTON, Pa., March 23, 2022 /PRNewswire/ — Spherix recently surveyed 76 gastroenterologists and 26 infectious disease (ID) physicians (including 8 qualitative interviews between both specialists) to gain perspective on the current and future management […]
Spherix Global Insights Finds US Primary Biliary Cholangitis Market Poised for Transformation as Pipeline Therapies Progress in Clinical Development
Four pipeline product profiles were evaluated by US gastroenterologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., March 16, 2022 /PRNewswire/ — Spherix recently surveyed 107 US gastroenterologists and conducted ten qualitative interviews (including a key opinion leader and six clinical trial participants) to assess the current and future management of primary biliary cholangitis (PBC). The […]
AbbVie Touts Qulipta Chronic Migraine Win as Biohaven Duel Heats Up
Oral CGRP inhibitors made by AbbVie and Biohaven Pharmaceuticals are quickly gaining share in the migraine market. But unlike their injectable peers, the two oral options have their prevention labels limited to episodic patients. That might change soon….
SGLT2 Inhibitors Are Gaining Momentum in Chronic and Diabetic Kidney Disease, New Spherix Data Reveals
Physician-reported and patient audit data reveal increased real world use of SGLT2 inhibitors (AstraZeneca’s Farxiga, Vifor/Janssen’s Invokana, Eli Lilly/Boehringer Ingelheim’s Jardiance and Merck’s Steglatro) among nephrologists’ CKD and DKD patients EXTON, Pa., / March 8, 2022 / PRNewswire – Nephrologists have historically had few options to help slow the progression of kidney disease in their […]
Roche’s Vabysmo to Offer ‘Fierce Competition’ to Regeneron’s Eylea, But a Long Market Battle Awaits: Spherix
Content Area
Ophthalmologists Welcome Genentech’s Vabysmo, Though Overthrowing Regeneron’s Eylea Will Be No Small Feat, Spherix Reports
Recent survey data reveals changes afoot in the neovascular (wet) age-related macular degeneration market EXTON, Pa., March 2, 2022 /PRNewswire/ — Spherix Global Insights, an independent market intelligence firm, recently collected feedback from 103 US ophthalmologists on the neovascular age-related macular degeneration (nAMD) treatment landscape. Insights from the RealTime Dynamix™ report revealed that market leader, […]
Argenx’s Vyvgart launch finds quick neurologist support over AstraZeneca’s well-entrenched Soliris for myasthenia gravis
Argenx nabbed an FDA approval for its rare disease drug Vyvgart just before Christmas and is wasting no time launching the generalized myasthenia gravis (gMG) med and setting it up to compete with AstraZeneca’s Soliris.
Gastroenterology Private Equity Acquisitions Grew 28% in 2021: 5 Stats to Know
Consolidation in gastroenterology accelerated in 2021, according to a recent report jointly published by consulting firm Fraser Healthcare and pharma research firm Spherix Global Insights. Here are five stats to know: 1. The number of private equity gastrointestinal groups grew by 28 percent to 68 in 2021…
AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’
AbbVie is going heavy on repetition with the first series of ads for its new preventative migraine drug, Qulipta. The drug, an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), was FDA-approved late last year to prevent episodic migraine and launched around three months ago. AbbVie, a major TV ad spender, has wasted no time getting […]
Argenx’s Vyvgart Offers a Substantial Advance Over Other Treatments for Generalized Myasthenia Gravis, Spherix Survey Suggests
Physician-reported treatment patterns suggest that Vyvgart prescriber base and share could soon be competitive with those of Alexion’s (now AstraZeneca’s) Solaris EXTON, Pa., February 14, 2022 / PRNewswire/ — At the end of last year, argenx’s Vyvgart (efgartigimod alfa-fcab) was approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients […]
